Patents by Inventor Sandrine Imbeaud

Sandrine Imbeaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy
    Publication number: 20220280655
    Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.
    Type: Application
    Filed: April 23, 2020
    Publication date: September 8, 2022
    Applicants: Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Genethon, Sorbonne Université, Universite de Paris, Université d'Evry-Val-d'Essonne, Universite Paris XIII Paris-Nord Villetaneuse
    Inventors: Jessica Zucman-Rossi, Jean-Charles Nault, Tiziana La Bella, Giuseppe Ronzitti, Sandrine Imbeaud, Patrice Vidal
  • Method for predicting responsiveness to a treatment with an EGFR inhibitor
    Patent number: 10400284
    Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: September 3, 2019
    Assignees: INTEGRAGEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Thomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud
  • METHOD FOR PREDICTING RESPONSIVENESS TO A TREATMENT WITH AN EGFR INHIBITOR
    Publication number: 20140370029
    Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
    Type: Application
    Filed: November 23, 2012
    Publication date: December 18, 2014
    Inventors: Thomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud